Danny Sullivan on Muck Rack

Danny Sullivan

Verified
Glasgow
As seen in: Longevity Technology, Flipboard, Citeline
Covers:  Longevity, aging, biotech, science
Contributing Editor at @LongevityTech. Writer, marketer, PR'er, traveller, reader, runner, technolover and lots of other ers...

Get in touch with Danny

Contact Danny, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Danny Sullivan’s Journalist Portfolio

Sir John Bell: 'No health system in the world is currently sustainable'

Sir John Bell: 'No health system in the world is currently sustainable'

The adage 'prevention is better than cure' has never been more relevant. And yet, health systems across the w…

View article →
Jim Mellon: Longevity could be the best investment you ever make

Jim Mellon: Longevity could be the best investment you ever make

In a few short weeks, The Longevity Week returns, bringing with it a host of compelling events and conference…

View article →
George Church: Learn from COVID and fast-track therapies that reverse aging

George Church: Learn from COVID and fast-track therapies that reverse aging

All eyes are on the Emerald Isle this week as the Longevity Summit Dublin brings together a host of speakers …

View article →

Articles

The ‘rising tide’ of mitochondrial therapies in longevity

|
By Danny Sullivan Verified
| Longevity Technology
In a landmark moment for biotech, the FDA last year granted accelerated approval to elamipretide, now marketed as Forzinity, to improve muscle strength in patients with a rare disease called Barth syndrome. The drug, developed by Stealth BioTherapeutics, became the first approved mitochondria-targeted therapeutic, marking a major milestone for the company, and for mitochondrial medicine more broadly.
Open in Who Shared Issue with article?

The ‘rising tide’ of mitochondrial therapies in longevity

|
By Danny Sullivan Verified
| Citeline Verified
In a landmark moment for biotech, the FDA last year granted accelerated approval to elamipretide, now marketed as Forzinity, to improve muscle strength in patients with a rare disease called Barth syndrome. The drug, developed by Stealth BioTherapeutics, became the first approved mitochondria-targeted therapeutic, marking a major milestone for the company, and for mitochondrial medicine more broadly.
Open in Who Shared Issue with article?

Herbalife to acquire personalized supplements company Bioniq

|
By Danny Sullivan Verified
| Longevity Technology
Supplements giant Herbalife has today announced an agreement to acquire Bioniq, a London-based company that offers personalized supplements based on its customers’ blood biomarkers and health data. The deal, which carries a total potential value of $150 million, is expected to complete in the second quarter of 2026, pending regulatory approvals.
Open in Who Shared View Duplicates (3) Issue with article?
See all 709 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified